Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies.

摘要

Chemoimmunotherapy has been the most significant step in recent years to improving overall survival (OS) and progression-free survival (PFS) rates in patients with diffuse large B-cell lymphoma (DLBCL).[1] Despite this major therapeutic advance, a significant proportion of patients will relapse or remain refractory to initial chemoimmunotherapy. The pivotal PARMA trial confirmed the place of high-dose chemotherapy and autolo-gous stem cell transplant (ASCT) as the optimum salvage treatment. [2] In the post-rituximab (Rituxan) era, patients with relapsed and refractory disease represent a different population than what was studied in the PARMA trial. [3] In this article, Hernandez-Iliza-liturri and Czuczman highlight the difficulty in managing such patients with salvage therapy and ASCT and raise the need for incorporating newer agents and strategies in this heterogeneous patient population.